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Abstract: Animal studies have shown that developmental exposures to polybrominated diphenyl
ethers (PBDE) permanently affect blood/liver balance of lipids. No human study has evaluated
associations between in utero exposures to persistent organic pollutants (POPs) and later life lipid
metabolism. In this pilot, maternal plasma levels of PBDEs (BDE-47, BDE-99, BDE-100, and BDE-153)
and polychlorinated biphenyls (PCB-138, PCB-153, and PCB-180) were determined at delivery in
participants of GESTation and Environment (GESTE) cohort. Total cholesterol (TCh), triglycerides
(TG), low- and high-density lipoproteins (LDL-C and HDL-C), total lipids (TL), and PBDEs were
determined in serum of 147 children at ages 6–7. General linear regression was used to estimate the
relationship between maternal POPs and child lipid levels with adjustment for potential confounders,
and adjustment for childhood POPs. In utero BDE-99 was associated with lower childhood levels of
TG (p = 0.003), and non-significantly with HDL-C (p = 0.06) and TL (p = 0.07). Maternal PCB-138 was
associated with lower childhood levels of TG (p = 0.04), LDL-C (p = 0.04), and TL (p = 0.02). Our data
indicate that in utero exposures to POPs may be associated with long lasting decrease in circulating
lipids in children, suggesting increased lipid accumulation in the liver, a mechanism involved in
NAFLD development, consistent with previously reported animal data.
Keywords: dyslipidemia; fetal programing; lipid metabolism; NAFLD; persistent organic pollutants
1. Introduction
Polybrominated diphenyl ethers (PBDEs) are related brominated organic chemicals
used widely as flame-retardants in synthetic materials, including clothing. Concentrations
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of PBDEs have increased in a broad range of environmental samples and human media
over approximately 30 years [1]. Despite withdrawal from the US market by 2013, current
human exposure to PBDEs remains close to their historical maximum in North America
due to their presence in consumer products and other materials in households and other
living locations. Some studies suggest that human PBDE burdens may even continue
to increase because of the persistence of PBDEs in the environment [2]. Because of their
lipophilicity and chemical stability [3,4] PBDEs accumulate in adipose tissue and are
mobilized in pregnancy [5]. As a result, the developing fetus is exposed via cord blood [5].
These findings are supported by the fact that PBDEs are found in the majority of fetal
samples in North America [6,7].
In the liver, there is an overlap between lipid metabolism and detoxification pathways
of drugs and xenobiotics. For example, xenobiotic-inducible nuclear receptors regulate
both xenobiotic metabolism and lipid homeostasis [8–18]. In addition, expression of hepatic
enzymes involved in metabolism of xenobiotics and lipids differ significantly by sex [19–24].
In humans, 1249 sex-specific genes have been identified in the liver [22], and found to be
enriched for lipid metabolism and cardiovascular disease among other biological categories.
These data suggest induction of lipid metabolism pathways after chemical exposures and
sexually dimorphic character of this response.
Concerningly, PBDEs exposure produce transient effects on lipid metabolism via
reversible induction of liver nuclear receptors, constitutive androstane receptor (CAR) and
pregnane X receptor (PXR) [25]. Recent rodent studies demonstrate however, that develop-
mental exposures to PBDEs may result in permanent effects on lipid metabolism leading to
dyslipidemia and a non-alcoholic fatty liver disease (NAFLD)-like phenotype [26,27]. The
molecular basis of these programing events is not well understood but likely includes liver
epigenome remodeling [28].
In this study, based on our results from animal studies [26,29], we hypothesized that
in utero exposures to PBDEs would produce long lasting effects in liver metabolism of
lipids in humans. To test this hypothesis, we evaluated the associations between maternal
blood organohalogens at delivery and lipid profiles of children at 6–7 years of age in the
prospective GESTation and Environment (GESTE) cohort.
2. Results
Our analysis of dyads with complete data on in utero exposure, age 6–7 childhood
lipids, and covariates represents substantial dropout in this longitudinal study among
women who provided blood samples and information at delivery. Comparisons of those
included in analysis (n = 147, 25%) with those who excluded due to dropout (n = 413, 75%)
identified small differences in age (29.3 vs. 28.4, p = 0.04) and BDE-153 (0.012 vs. 0.022,
p = 0.03), but no differences were observed in other in utero chemical concentrations or
BMI. In addition, at baseline, only a subset of women chose to participate in follow-up
visits, further suggesting randomness to dropout and low probability of selection bias as
a result.
Sample summary statistics are presented in Tables 1 and 2. Table 1 displays participant-
pair (n = 147) characteristics and serum levels for selected metals by tertiles of child’s total
lipid levels. Maternal age significantly (p < 0.05) varied by total lipid levels. Manganese
levels at delivery also varied significantly by total lipids; however, this variable was not
associated with any of the individual PCBs, PBDEs, or the PCB or PBDE summation
variables (range of t-test p-values: 0.53–0.996, data not shown). Based on bivariate analyses,
maternal age at pregnancy and post-pregnancy BMI were included as potential confounders
in adjusted, multivariable models.
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Table 1. Participant-Pairs Characteristics by Total Lipid Tertiles (mmol/L). GESTE Cohort.
Tertile 1, n = 51
(Lower-Upper) +
Tertile 2, n = 45
(Lower-Upper) +
Tertile 3, n = 51
(Lower-Upper) +
4.05 0.35 4.72 0.15 5.55 0.46
Mean * (SD) Mean * (SD) Mean * (SD) p #
Maternal age (years) at pregnancy 30.3 (3.9) 30.0 (4.4) 27.8 (4.9) 0.009
Maternal BMI after delivery 26.7 (4.5) 26.6 (5.3) 27.4 (6.2) 0.76
Child BMI at age 6–7 years 15.8 (1.4) 15.9 (1.5) 15.9 (1.9) 0.95
PCB Sum (ng/mL) 0.090 (3.34) 0.086 (2.71) 0.066 (4.63) 0.43
BDE Sum (ng/mL) 0.135 (3.56) 0.123 (3.66) 0.155 (3.93) 0.68
Triglycerides (mmol/L) 0.697 (1.39) 0.794 (1.36) 1.393 (1.43) <0.0001
Maternal serum lead levels at delivery (umol/L) 0.037 (1.46) 0.037 (1.62) 0.041 (1.71) 0.35
Maternal serum manganese levels at delivery (nmol/L) 247.0 (1.27) 253.3 (1.35) 282.0 (1.29) 0.03
Maternal serum cadmium levels at delivery (nmol/L) 2.008 (2.09) 1.716 (1.65) 2.117 (2.02) 0.29
Maternal serum mercury levels at delivery (µg/L) 2.585 (2.00) 2.740 (1.67) 2.351 (2.04) 0.51
Child serum lead levels at 6–7 years (umol/L) 0.033 (1.58) 0.037 (1.52) 0.035 (1.53) 0.54
Child serum manganese levels at 6–7 years (nmol/L) 172.2 (1.32) 185.6 (1.30) 178.8 (1.27) 0.37
Child serum cadmium levels at 6–7 years (nmol/L) 0.800 (1.41) 0.795 (1.31) 0.803 (1.27) 0.99
Child serum mercury levels at 6–7 years (µg/L) 1.569 (1.83) 1.474 (1.88) 1.512 (1.84) 0.88
% % %
% Female child 35.3% 48.9% 49.0% 0.28
% Reported smoking during pregnancy a 6.0% 0.0% 7.8% 0.18
% Reported alcohol use during pregnancy a 30.0% 25.0% 25.5% 0.83
% Vaginal delivery a 82.4% 75.6% 84.3% 0.53
Maternal educational level
0.42
Primary 0.0% 0.0% 2.0%
Secondary 9.8% 8.9% 19.6%
College 19.6% 24.4% 29.4%
University 35.3% 42.2% 27.5%
Other 31.3% 22.2% 21.6%
Missing 3.9% 2.2% 0.0%
Abbreviations: SD-standard deviation, BMI-body mass index (kilograms/(meters2)), PCB-Polychlorinated biphenyl, BDE-
Decabromodiphenyl ether. + Lower and upper bounds for the tertiles of total lipids, measured by Phillip’s Method, in mmol/L.
* Mean and SD represent geometric mean and geometric SD. # p-Value from one-way ANOVA for all linear characteristics. For cate-
gorical characteristics, Chi-Squared tests were used except for smoking and maternal education level, which required Fisher’s Test. a. These
groups had 2 participants with missing information.
Table 2. Distributions of organohalogens (ng/mL) among mothers within GESTE cohort.
% below LOC Minimum 25% Q1 50% Median 75% Q3 Maximum Q3 ÷ Q1
BDE 47 0% 0.00035 0.020 0.05 0.11 1.05 5.6
BDE 99 13% 0.00005 0.004 0.02 0.06 0.64 14.1
BDE 100 12% 0.00005 0.010 0.02 0.06 0.43 5.8
BDE 153 16% 0.00005 0.008 0.03 0.06 0.87 8.3
Sum BDEs – 0.00241 0.064 0.14 0.34 2.49 5.3
PCB 138 20% 0.00001 0.002 0.02 0.04 0.27 18.1
PCB 153 5% 0.00001 0.024 0.05 0.07 0.41 3.0
PCB 180 10% 0.00001 0.009 0.03 0.05 0.26 4.8
Sum PCBs – 0.00003 0.039 0.09 0.16 0.91 4.1
Sum of All
Organohalogens – 0.00244 0.14 0.27 0.55 2.64 3.9
Total number of participants included in analyses was 147. Abbreviations: PCB-Polychlorinated biphenyl, BDE-Decabromodiphenyl ether.
Overall, most POPs were not strongly associated with childhood lipid levels in simple
or adjusted models; however, PCB-138 and BDE-99 were moderately (p < 0.10) or signif-
icantly (p < 0.05) associated with multiple lipid measurements (Table 3). PCB-138 was
associated significantly with TG (p = 0.04), LDL-C (p = 0.04) and TL (p = 0.02) and associated
moderately with TCh (p = 0.09) and HDL-C (p = 0.07). BDE-99 was significantly associated
with TG (p = 0.003) and moderately associated with HDL-C (p = 0.06) and TL (p = 0.07)
(Table 3). Additionally, PCB-180 was significantly associated with TG (p = 0.03) and sum
of PCB was moderately associated with TL (p = 0.09). Associations between HDL-C and
PCB-138 or BDE-99 were positive, while all other moderate and significant associations
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between lipid parameters and POPs were negative. Tertile analyses supported analyzing
associations as linear relationships (data not shown).
Table 3. Relationship between Chemical Exposures Levels at Delivery and Child Lipid Levels at
6–7 years in the GESTE Cohort.
Bivariate Model Multivariate Model +
Chemical Beta SE p Beta SE p
Cholesterol a
PCB 138 −0.028 (0.014) 0.04 −0.024 (0.014) 0.09
PCB 153 −0.029 (0.022) ** −0.022 (0.022) **
PCB 180 −0.003 (0.019) ** 0.001 (0.018) **
Sum PCB −0.062 (0.037) 0.09 −0.046 (0.037) **
BDE 47 0.020 (0.032) ** 0.029 (0.031) **
BDE 100 −0.005 (0.020) ** −0.004 (0.019) **
BDE 99 0.002 (0.018) ** 0.003 (0.018) **
BDE 153 −0.009 (0.017) ** −0.006 (0.017) **
Sum BDE 0.011 (0.036) ** 0.015 (0.035) **
Sum OH −0.021 (0.045) ** −0.007 (0.044) **
HDL b
PCB 138 0.018 (0.010) 0.06 0.018 (0.010) 0.07
PCB 153 −0.001 (0.016) ** −0.002 (0.016) **
PCB 180 0.015 (0.013) ** 0.015 (0.013) **
Sum PCB 0.023 (0.026) ** 0.022 (0.027) **
BDE 47 0.026 (0.022) ** 0.025 (0.022) **
BDE 100 0.021 (0.013) ** 0.021 (0.014) **
BDE 99 0.024 (0.013) 0.06 0.024 (0.013) 0.06
BDE 153 0.006 (0.012) ** 0.005 (0.012) **
Sum BDE 0.041 (0.025) ** 0.041 (0.025) **
Sum OH 0.043 (0.031) ** 0.042 (0.031) **
LDL a
PCB 138 −0.026 (0.014) 0.06 −0.022 (0.013) **
PCB 153 −0.026 (0.022) ** −0.022 (0.022) **
PCB 180 0.011 (0.018) ** 0.014 (0.018) **
Sum PCB −0.049 (0.036) ** −0.037 (0.036) **
BDE 47 0.012 (0.031) ** 0.022 (0.030) **
BDE 100 −0.010 (0.019) ** −0.007 (0.019) **
BDE 99 0.012 (0.018) ** 0.014 (0.018) **
BDE 153 −0.017 (0.017) ** −0.013 (0.016) **
Sum BDE 0.005 (0.035) ** 0.011 (0.034) **
Sum OH −0.008 (0.043) ** 0.004 (0.043) **
Triglycerides b
PCB 138 −0.026 (0.011) 0.02 −0.023 (0.011) 0.04
PCB 153 −0.008 (0.018) ** 0.000 (0.018) **
PCB 180 −0.033 (0.015) 0.02 −0.032 (0.015) 0.03
Sum PCB −0.046 (0.029) ** −0.035 (0.030) **
BDE 47 −0.015 (0.025) ** −0.018 (0.025) **
BDE 100 −0.014 (0.016) ** −0.016 (0.015) **
BDE 99 −0.041 (0.014) 0.01 −0.043 (0.014) 0.003
BDE 153 0.016 (0.014) ** 0.015 (0.014) **
Sum BDE −0.024 (0.029) ** −0.028 (0.028) **
Sum OH −0.060 (0.035) 0.09 −0.055 (0.035) **
Total lipids b
PCB 138 −0.010 (0.004) 0.01 −0.009 (0.004) 0.02
PCB 153 −0.007 (0.006) ** −0.004 (0.006) **
PCB 180 −0.008 (0.005) ** −0.007 (0.005) **
Sum PCB −0.022 (0.010) 0.02 −0.017 (0.010) 0.09
BDE 47 0.001 (0.008) ** 0.002 (0.008) **
BDE 100 −0.004 (0.005) ** −0.004 (0.005) **
BDE 99 −0.008 (0.005) 0.09 −0.009 (0.005) 0.07
BDE 153 0.001 (0.005) ** 0.001 (0.005) **
Sum BDE −0.004 (0.010) ** −0.004 (0.009) **
Sum OH −0.017 (0.012) ** −0.013 (0.012) **
Abbreviations: SE-standard error, P-T-test p-value, HDL-high density lipoproteins, LDL-low density lipoproteins,
PCB-polychlorinated biphenyl, BDE-brominated diphenyl ether, OH-organohalogens. a Beta and SE from model
using cholesterol untransformed and log transformed chemicals. b Beta and SE from model using log transformed
exposure and log transformed outcome. ** p-value from T-test ≥ 0.10. + Adjusted for mother’s age during
pregnancy and mother’s body mass index after delivery.
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We conducted analysis to address potential confounding by childhood chemical levels,
which could result in a misattribution of effects of chemical exposure in childhood on lipids
as being due to in utero exposure. Because of a primary goal to assess and control for
confounding, we first evaluated correlations between in utero chemical levels and those
measured in children age 6–7 (Supplemental Table S1) and observed mostly weak relations
between maternal chemical levels and those among children at age 6–7. Levels of childhood
BDE-153 were correlated with maternal delivery values for BDE-100 (r = 0.24, p =0.005) and
BDE-153 (0.34, p <0.0001) (n = 140 child-mother pairs). We ran main analyses adjusted for
BDE-153 to estimate in utero effects independent of childhood chemical levels (Figure S1)
(n = 136 child-mother pairs). Generally, results remained the same or were strengthened.
We also conducted analysis to evaluate the relationship between age 6–7 years old PBDE
exposures with serum lipids (Supplemental Table S2). For these analyses, we utilized wet
weight chemicals in order to avoid adjusting exposure for the dependent variable and
resulting bias along with interpretational challenges. Associations between childhood
levels of BDE-47 and 99 were observed with lower HDL-C and higher LDL-C. BDE-100
was also associated with lower HDL-C.
Analyses stratified by child sex suggested sex-specific associations (Figure 1). In the
majority of stratified analyses, the associations among girls and boys were not equivalent to
one another nor the non-stratified (“All”) results and followed a similar trend. Nevertheless,
tests for interactions between chemical and child sex were not significant in bivariate or
adjusted models (Table 4).
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Figure 1. Correlations between in utero POP levels and blood lipids in children in the GESTE cohort, overall and separate by
child sex: (A)—total cholesterol; (B)—high density lipoproteins; (C)—low density lipoproteins, (D)—triglycerides; (E)—total
lipids. Linear regression coefficients are shown from models of lipids measured in children at age 6–7 from the GESTE
cohort and in utero levels of PCBs and PBDEs. Squares indicate results in the full cohort (n = 147); offspring sex-specific
estimates are shown with circles (in male offspring only, n = 82) and diamonds (female offspring only, n = 65).
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Table 4. Interaction between Chemical Exposures Levels at Delivery and Child Biological Sex on
Child Lipid Levels at 6–7 years in the GESTE Cohort.
Bivariate Model Multivariate Model +
Chemical p * p *
Cholesterol a
PCB 138 0.66 0.75
PCB 153 0.36 0.34
PCB 180 0.34 0.22
Sum PCB 0.16 0.14
BDE 47 0.16 0.18
BDE 100 0.47 0.55
BDE 99 0.98 0.75
BDE 153 0.94 0.99
Sum BDE 0.48 0.52
Sum OH 0.27 0.33
HDL b
PCB 138 0.56 0.56
PCB 153 0.45 0.46
PCB 180 0.29 0.29
Sum PCB 0.35 0.35
BDE 47 0.85 0.85
BDE 100 0.93 0.93
BDE 99 0.48 0.50
BDE 153 0.85 0.85
Sum BDE 0.97 0.96
Sum OH 0.62 0.63
LDL a
PCB 138 0.69 0.77
PCB 153 0.24 0.21
PCB 180 0.16 0.08
Sum PCB 0.15 0.13
BDE 47 0.17 0.19
BDE 100 0.34 0.41
BDE 99 0.70 0.92
BDE 153 0.91 0.85
Sum BDE 0.42 0.46
Sum OH 0.28 0.34
Triglycerides b
PCB 138 0.12 0.16
PCB 153 0.25 0.32
PCB 180 0.46 0.56
Sum PCB 0.02 0.02
BDE 47 0.76 0.76
BDE 100 0.07 0.08
BDE 99 0.996 0.88
BDE 153 0.86 0.80
Sum BDE 0.50 0.55
Sum OH 0.38 0.36
Total lipids b
PCB 138 0.28 0.37
PCB 153 0.26 0.28
PCB 180 0.30 0.25
Sum PCB 0.03 0.03
BDE 47 0.47 0.51
BDE 100 0.59 0.53
BDE 99 0.95 0.70
BDE 153 0.97 0.96
Sum BDE 0.99 0.99
Sum OH 0.23 0.27
Abbreviations: SE-standard error, P-T-test p-value, HDL-high density lipoproteins, LDL-low density lipoproteins,
PCB-polychlorinated biphenyl, BDE-brominated diphenyl ether, OH-organohalogens. a Beta and SE from
model using cholesterol untransformed and log transformed chemicals. b Beta and SE from model using log
transformed exposure and log transformed outcome. * p-value from Type 3 F-test. + Adjusted for mother’s
age during pregnancy and mother’s body mass index after delivery. Bold values indicate significant and semi-
significant findings.
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3. Discussion
Several rodent studies observed long-term programing of lipid metabolism by in utero
exposures to POPs [26,27,29–31]. Results from the current study of mother-child pairs in
the GESTE cohort suggest that these previously reported findings may apply for humans,
as well. In mice, we have found that in utero exposure to PBDEs causes a shift of lipid
balance between the liver and blood, whereby increased uptake and accumulation of lipids
by the liver results in decreased TG in blood and a NAFLD-like liver phenotype. In our
current study, we also observe decreased TG in blood associated with in utero exposures to
BDE-99 and PCB-138. Additionally, in utero levels of BDE-99 were associated with lower
total lipids, and those of PCB-138 were associated with lower LDL-C and total blood lipids
in 6–7-year-old children. These associations between in utero POPs and lower plasma lipid
levels are consistent with increased uptake of fatty acids by the liver and may indicate
higher fat accumulation in children’s livers.
Notably, PCB-138 and BDE-99 had the broadest normalized ranges of exposures
among all compounds analyzed, suggesting that weaker associations between other POPs
at delivery and lipid profiles at childhood may be due to our limited ability to detect
them and/or distribution in the study sample, rather than due to the lack of biological
link between exposures and outcomes. In addition, adjustment for POPs measured in
childhood plasma samples did not weaken estimates of the in utero exposure effects as
represented by maternal plasma levels. The potential for childhood POPs to confound the
relationship of in utero exposure with childhood lipid levels depends upon common causes
that result in correlation between exposure at these two time points. We did not observe
such a correlation in our data, suggesting no substantial confounding of the relationship of
interest. This provides further support that association between in utero POPs are due to
programing effects rather than due to continuous exposures lasting into childhood, though
caution is warranted to acknowledge the potential for chance findings
Further, we observed indication that programing is sexually dimorphic and that the
relationship between in utero POPs and lipid profile in children is sex specific. Because our
analysis was inherently restricted to dyads with available data on both in utero chemical
levels and childhood lipid levels, our sample size was modest and we had limited statistical
power to detect interactions. In analyses stratified on offspring sex, we observed consistent
differences in the associations of in utero POPs and childhood lipids. This observation is
in agreement with our hypothesis that sex specificity in liver metabolic functions results
in modified response of lipid liver metabolism to chemical exposures. Our limited ability
to find significant effect of sex may be also explained by the young age of the study
participants. Liver sex specificity is generally thought to be established after the onset of
puberty, when growth hormone secretion reaches clear sexually dimorphic patterns [32].
Resent research has demonstrated however, that even late gestation fetal livers have
well-pronounced sex-specific pattern of gene expression in mice and more than 70% of
fetal sex-biased genes overlap with adult sex-biased genes [33]. Comparable data are not
available for humans to our knowledge.
To the best of our knowledge, this study is the first epidemiologic investigation of a
putative link between in utero exposures to PCBs and PBDEs and long-term changes in
serum lipids in humans. Exposure, levels to PBDEs in the GESTE cohort are comparable
with exposure levels in many studies in the North America as compared elsewhere [34,35].
Maternal plasma levels of PCBs were very close to these in a representative sampling
of the U.S. population in the National Health and Examination Survey [36]. Effects of
developmental exposures to PBDE on permanent changes in liver lipid metabolism and
circulating lipids have been shown in several rodent studies [26,27,29–31]. For example,
mice exposed to low doses of BDE-47 perinatally and then kept on a high fat diet for
14 weeks developed dyslipidemia and hepatic steatosis [27]. A significant body of literature
exists linking adult exposure to PCBs with altered lipid metabolism, including NAFLD
promotion [37]. We were unable to identify studies in which long lasting changes in
lipid metabolism outcomes were analyzed following developmental exposures to PCB.
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However, in four-month-old rats exposed perinatally to non-dioxin-like PCBs changes in
gene expression in blood were significantly enriched for lipid metabolism [38].
Transient activation of liver Phase I-III enzymes via induction of nuclear receptors
(xenosensors) by a broad range of xenobiotics is one of the central concepts in toxicology.
Given that this same set of nuclear receptors regulates lipid homeostasis [8–18], potential
short-term responses to xenobiotics include transient changes in liver lipid metabolism.
PBDEs and PCBs are no exception to this rule, as both groups of chemicals are ligands for
CAR and PXR xenosensors [25]. In other words, acute effects of PBDE and PCB on lipid
levels are predictable and represent a common toxicological response. Positive associations
of childhood LDL-C with childhood levels of BDE 47 and 99, as well as negative associations
of childhood HDL-C with childhood levels of BDE 47, 99 and 100 correspond to this type
of response. These results indicate that ongoing exposures to PBDE may represent a risk
factor for cardiovascular disease by shifting the lipid balance toward an increase in “bad
cholesterol” and decrease in “good cholesterol” levels.
The major focus of the current study is of a different nature however, as it relates to
long-term programing by in utero exposures. Clinically, this is of significance because
chronic health conditions arising from in utero programing affect health throughout the
lifespan. Molecular mechanisms involved in this programing are not well understood.
Our recent studies in rodents suggest that transient activation of the central metabolic
master switch, the mTOR pathway [39], in the liver by developmental exposures to PBDE
may result in permanent reprograming of the liver lipid metabolism [26,29] involving
changes in the profile of hepatic small non-coding RNA and DNA methylation [28]. It
is not clear, however if mTOR activation is mediated via CAR and/or PXR signaling.
Understanding of the initial steps triggering liver metabolism reprograming is complicated
by the presence of several transcript variants of CAR [40] and PXR [41], which may have
different affinity for different PCB and PBDE congeners; their different downstream mode
of action [42]; and emerging evidence of mechanistic links between these receptors and the
mTOR pathway [42,43]. Additionally, effects of lipid metabolism reprograming by POPs
may have different effects in males and females due to the sex-specific differences in liver
expression of many lipid metabolism genes [22].
Higher lipid uptake by the liver due to long term effects of in utero exposure to POPs,
as we report for some chemicals in this pilot study, may contribute to pediatric NAFLD,
the most common chronic liver disease in American children [44–46] with an estimated
prevalence of 13% [45]. Emerging data demonstrates that pediatric NAFLD may be a more
aggressive form of liver disease than adult NAFLD [47]. For example, in a recent study
of children with NAFLD, one third of participants developed nonalcoholic steatohepatitis
(NASH) or worsening of fibrosis in a 2-year period [48]. Severely obese adolescents have
significantly higher NASH incidence and liver fibrosis then adults [49]. Pediatric NAFLD is
associated with greater liver-related morbidity and mortality in adulthood [50]. Identifying
potentially modifiable factors that contribute to these outcomes, and development of future
interventions, is thus of great public health significance.
Some limitations and cautions are important to note. In our analysis, we expressed
PCB and PBDE concentrations per blood volume without adjustment for blood lipids. For
our study of in utero POPs, fetal exposure results from total POPs delivered to placenta via
maternal circulation regardless of maternal body burden. The lipophilic nature of PCBs
and PBDEs presents a challenge for environmental epidemiologic research, and thoughtful
consideration of the underlying biology is a critical step to guide statistical analysis [51].
Lipid normalization is not appropriate when circulating chemical levels, rather than total
body burden, is the biologically relevant tissue [51]. Additionally, lipid profile itself may
be affected by exposures to POPs [26,29,52–54]. For statistical modeling of outcomes
affected by lipids, or lipids themselves, adjustment or use of lipid standardization results
in bias to the parameter of interest [51]. Finally, in blood, many POPs are bound to blood
proteins. For example, PBDEs and their metabolites have high affinity to transthyretin
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in humans [55–57] and to major urinary protein in mice [58]. In that case, adjustment for
lipids is not relevant for any biologically meaningful estimation of exposure.
Uncontrolled confounding is always a potential source of bias for observational re-
search. Nevertheless, we were able to adjust for factors including child chemical levels
and other variables from the rich GESTE dataset that might represent confounders. Re-
assuringly, adjustment for covariates had minimal effect on estimates. Thus, through
some variables play roles in the relationship of in utero exposure and child lipid levels
that are uncertain, such as adiposity which may be a confounder or causal intermediate,
results were not impacted. A priori power calculations for this exploratory study suggested
adequate sample size for the study but did not explicitly address the multiple comparisons
due to the number of chemical exposures and lipid outcomes. Results of this exploratory
study should be interpreted with caution, accordingly.
One limitation of this study is that lipids were analyzed in non-fasting blood samples
collected from children. As a result, child lipid levels are subject to post-prandial variation.
Recent studies suggest however, that non-fasting total cholesterol, HDL-C and LDL-C
change minimally in response to food intake and may be superior to fasting levels in
predicting adverse health outcomes [59–63]. Specifically, a cross-sectional study of more
than 200,000 lipid profiles [64] observed that fasting times account for less than 2% variation
for total cholesterol and HDL-C and less than 20% for TG. Given that humans are rarely
present in fasting state, non-fasting lipids may better present individual molecular reactions
of the organism for lipid intake. As such, non-fasting lipid profiles are becoming more
popular as markers of health conditions in clinical guidelines [65–68]. Thus, using non-
fasting lipids in our study is a moderate limitation as it represents one clinically relevant
way to assess lipid profiles. No systematic error is anticipated from this procedure as soon
as all within study comparisons are based on non-fasting lipids.
4. Materials and Methods
4.1. Participants
We conducted analyses using data from the prospective GESTE cohort, which is de-
scribed in detail elsewhere [34,35,69,70]. In short, GESTE cohort is comprised of (a) women
residing in the Eastern Townships (Estrie) of Quebec, Canada having a pregnancy between
2007 and 2009 and (b) children born from these pregnancies. Women were recruited at
their first prenatal visit by 20 weeks gestational age (n = 400, at >20 weeks), or at delivery
(n = 400 additional women) at the Research Center of the Centre Hospitalier Universitaire
de Sherbrooke (CHUS). Eligible criteria included women ≥18 years old at their first prena-
tal visit without thyroid diseases, who were planning on residing in the Estrie for at least
three years. At delivery, only healthy, uncomplicated term pregnancies were included in
the cohort.
Our study population was restricted to maternal-child dyads including women with
singleton pregnancies, having complete data for maternal PBDEs at delivery as well as a
lipid profile performed at age 6–7 years old. After applying these inclusion criteria, a total
of 147 observations were included for analysis.
The Institutional Review Boards of the CHUS, Université de Sherbrooke (IRB # 05-
057-S1, 2008-103), Health Canada (REB 2017-035H) and the University of Massachusetts,
Amherst (IRB # 2019-5622), approved study protocols, and women provided informed
consent for themselves and their children.
4.2. Data Collection
Data were collected and managed using the secure online platform REDCap [71].
Non-fasting maternal blood was collected at delivery in 10-mL Vacutainer® Hemogard
tubes with ethylenediaminetetraacetic acid (ref. 366643, Becton-Dickinson, San Jose, CA,
USA). The plasma was frozen at −20 ◦C in decontaminated Supelco glass storage tubes
(Supelco, Inc., Bellefonte, PA, USA) for PBDEs and PCBs. In addition, 10-mL metal-free
blood collection tubes with 0.05 mL of 15% ethylenediaminetetraacetic acid K3 stored at 4
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◦C were used for manganese, lead, mercury and cadmium analysis. At the age of 6–7 years
old, ten mL of non-fasting whole blood were taken from each child using a BD Vacutainer®
tubes (ref. 367962, Becton Dickinson, Franklin Lakes, NY, USA) containing lithium-heparin
for the analysis of PBDEs and lipid profiles. Non fasting blood samples were stored at
−80 ◦C and analyzed for lipid profiles in the core laboratory of the CHUS.
4.3. Exposure Assessment–PBDEs and PCBs in Utero and at 6–7
Maternal plasma levels of PBDEs (BDE-47, BDE-99, BDE-100, and BDE-153) and PCBs
(PCB-138, PCB-153, and PCB-180) were analyzed in the laboratory of L. Takser (Université
de Sherbrooke) using the method described by Covaci and Voorspoels [72]. As previously
described, [34,35], analytes were quantified using Varian 4000 Ion Trap GC/MS-MS (gas
chromatograph/tandem mass spectrometer) (Varian Inc., CA, USA). Quality control was
conducted through regular analyses of water blanks, solvent blanks and random duplicate
samples. All blanks were subtracted from sample values on a batch basis. Inter-batch
coefficients of variation were ≤10% and ≤8% for PBDEs and PCBs, respectively. Limits
of detection (LOD), defined as 3 times the noise level, were established at 0.1 pg/µL for
PBDEs and at 0.02 pg/µL for PCBs. Routine checks of accuracy and precision were also
performed using reference materials (1589a) from the National Institute of Standards and
Technology (Gaithersburg, MD, USA). Recoveries ranged between 75 and 125%.
Child plasma PBDE levels were analyzed in the laboratory of J. Zhu (Health Canada).
Analytical procedures are described in detail elsewhere [69]. In short, analytes were
quantified using an Agilent 7890A GC coupled with 7200 QTOF MS (Agilent Technologies,
Santa Clara, CA, USA). Quality control was conducted through regular analyses of water
blanks, commercial human serum (S7023, Sigma Aldrich, MO, USA) that was spiked with
target analytes, and random duplicate samples. All blanks were subtracted from sample
values on a batch basis. Inter-batch coefficients of variation were in a range between
1% and 9% for different PBDE congeners. Compound specific limit of detection (LOD)
was estimated to be in the range of 1–5 pg/g wet weight. Mean recoveries were in the
range of 94–125%, except for BDE-183 (59.6%). The concentrations of target analytes in the
samples were recovery-corrected against BDE-138, a congener that was not present in the
environment and humans, as the surrogate standard.
4.4. Outcome Assessment–Lipid Profiles in Children at Age 6–7
The lipid work-up was performed in the the biochemistry laboratory of the CHUS.
Fresh blood samples were centrifuged at 1300–2000 g for 10 min to separate the plasma
from the whole blood within 1 h after collection. Samples were stored at −80 ◦C. Total
cholesterol (TCh) (assay ref. 5168538), total triglycerides (TG) (assay ref. 5171407), and
high density lipoproteins (HDL-C) (assay ref. 5168805) were analyzed using enzymatic
colorimetric method using a Roche Cobas 8000 analyzer with commercial c702 kit, following
manufacturer’s instructions (Roche Diagnostics, Germany). The assay was calibrated for
each new reagent bottle or batch or when required by internal control. Analytical variation
and systematic error were both below 3% [69]. Lower limits of detection (LOD) were
0.1 mmol/L (3.86 mg/dL) for TCh, 0.08 mmol/L (3 mg/dL) for HDL-C and 0.1 mmol/L
(8.85 mg/dL) for TG. Concentration of low-density lipoproteins (LDL-C) was estimated
using the Friedewald formula (LDL = TCh − HDL − TG/2.2) [73] and concentration of
total lipids (TL) was estimated using Phillips formula (TL = 2.27TCh + TG + 0.62) [74,75].
4.5. Additional Covariates in GESTE
Additional data collected in the GESTE study were utilized to characterize the study
sample and to address potential confounding by factors with effects on child lipid levels
and correlated with in utero POPs. Questionnaires were administered by interviewers at
the first prenatal visit and after delivery and were used to collect information on education,
income, alcohol consumption, smoking and other factors [35]. Trained staff measured
women’s height and weight at the enrolment visit and collected self-reported information
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on the usual weight and height after delivery. Children’s height and weight was similarly
assessed at the age 6–7 years old. All data on maternal health and obstetrical history,
medication use, and delivery were obtained from medical records.
In addition to questionnaire data, data for metals was considered as metal expo-
sures have been shown in many studies to affect lipid metabolism (reviewed in [76]).
Whole blood manganese, lead, cadmium and mercury were determined by the Toxicology
Center of Quebec at the Quebec Institute for Public Health (CTQ-INSPQ) as described
elsewhere [34,35]. In short, cold vapor atomic absorption spectrophotometry was used for
total blood mercury and mass spectrometry plasma torch (ICP-MS) for lead, cadmium and
manganese. Limits of detection were 2.07 µg/L for lead, 0.1 µg/L for mercury, 0.05 µg/L
for cadmium, and 4.4 µg/L for manganese.
4.6. Data Management and Statistical Analyses
Chemical levels below the LOD were set to LOD/2. In order to address outliers related
to measurement error and undue leverage in analysis, values higher than 3.5 standard
deviations above the mean were replaced by this cut point [77]. Some variables were natural
log transformed based on the visual inspections of distributions to meet distributional
assumptions for statistical modeling.
Generalized linear models (GLM) were used to evaluate the relation of childhood
lipid levels as continuous variables with in utero POPs. The interpretation of regression
coefficients varies depending on whether a log transformation was used for independent
and dependent variables. In recognition of the limited statistical power for this pilot study, a
conservative approach to specifying multivariable models was used to build parsimonious
models, aimed at maximizing statistical power while controlling for confounding. Using
underlying biology and existing literature, a priori potential confounding factors based on
plausible causal relations with child lipid levels and POP exposures was identified. These
a priori potential confounders included: maternal age (years); smoking during pregnancy;
alcohol using during pregnancy; child sex (male/female); maternal education; maternal
body mass index at 1st trimester and after delivery (BMI, (weight (kg) /[height (m)]2));
child’s weight and BMI at age 6–7; delivery type (vaginal, caesarean, missing); gestational
diabetes during current pregnancy; maternal delivery and 6–7 year children’s serum levels
of lead, cadmium, manganese, and mercury. Only those factors related to both outcome and
exposure (p < 0.20) were retained in final models to address confounding, as determined
from ANOVA for categorical variables and generalized linear models for continuous
variables. For the primary statistical models of lipids, chemical exposures were included as
continuous variables. To evaluate departures from the assumption of linearity in the GLM
models, chemical exposures were categorized into tertiles. Regression models of serum
lipid outcomes were run as non-parametric assessments of dose–response patterns.
We utilized data on age 6–7 child chemical levels to account for potential confounding
of in utero chemical effects by later life exposure. Using available data on chemical levels
measured at age 6–7 (including BDE-100, BDE-99, BDE-153, and BDE-183), we evaluated
associations with maternal delivery levels by correlation analysis, and associations with
child lipid levels using GLMs. Finally, multivariable regression models were run including
childhood POPs related to in utero exposures and child lipid outcomes as covariates in
order to estimate effects of in utero exposure independent of later life chemical levels.
In addition to the main analyses described above, we evaluated differences by off-
spring sex to address sex-differences in associations by performing stratified analyses as
well as including a cross-product interaction term. This interaction term was used to test
additive interaction between child sex and exposure. For all analyses, statistical significance
was defined as p-values < 0.05.
5. Conclusions
In the current study, our data are consistent with long-term effects of in utero envi-
ronmental exposures to PCB and PBDE on blood lipids, previously observed in murine
Metabolites 2021, 11, 657 12 of 15
models, but to this date, not assessed in humans. Relationships between higher in utero
POPs and lower childhood blood lipids may indicate increased lipid accumulation in
livers, a mechanism of NAFLD development. Additionally, we observed shift in children
lipid profiles by ongoing exposures to several PBDE congeners, consisting in the increased
LDL-C and decreased HDL-C, a potential risk factor for cardiovascular disease. Our study
provides suggestion that long-term changes in blood lipids may be sexually dimorphic,
in line with well-established sexual dimorphism in liver physiology. Given the modest
sample size of our study and recognition that this sexual dimorphism and implications
for lipid metabolism increase drastically after puberty, further research on bigger child
cohorts as well as on adult subjects is needed to study long-term programing of liver lipid
metabolism and sex-specific effects of developmental exposures to POPs.
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